secwatch / observer
8-K filed March 18, 2025, 7:59 PM ET ticker RXRX CIK 0001601830
leadership confidence high sentiment positive materiality 0.55

Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board

RECURSION PHARMACEUTICALS, INC.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001601830-25-000040
form_type
8-K
ticker
RXRX
cik
0001601830
company_name
RECURSION PHARMACEUTICALS, INC.
filed_at
2025-03-18T23:59:59+00:00
discovered_at
2026-05-14T18:03:04.155391+00:00
generated_at
2026-05-24T13:41:36.773608+00:00
sec_items
["5.02", "7.01", "8.01", "9.01"]
event_type
leadership
sentiment
positive
materiality_score
0.55
calibrated_materiality_score
0.55
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001601830-25-000040
json_url
https://secwatch.observer/filing/0001601830-25-000040.json
markdown_url
https://secwatch.observer/filing/0001601830-25-000040.md
text_url
https://secwatch.observer/filing/0001601830-25-000040.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/rxrx-20250315.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elaine Sun

Director
RXRX · RECURSION PHARMACEUTICALS, INC.
Effective
2025-03-15
Filed
March 18, 2025, 7:59 PM ET
The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.
Appointed

Dr. Namandjé Bumpus

Director
RXRX · RECURSION PHARMACEUTICALS, INC.
Effective
2025-03-15
Filed
March 18, 2025, 7:59 PM ET
The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.

Source-grounded claims

03be3c1dd6

Elaine Sun was appointed as Director at RECURSION PHARMACEUTICALS, INC..

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

a237a18340

Dr. Namandjé Bumpus was appointed as Director at RECURSION PHARMACEUTICALS, INC..

The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

Comparable filings

CRVL

CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026

CORVEL CORP June 1, 2026, 5:05 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.

Filing page SEC filing

WST

West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair

WEST PHARMACEUTICAL SERVICES INC June 1, 2026, 4:32 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.

Filing page SEC filing

LPX

LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026

LOUISIANA-PACIFIC CORP June 1, 2026, 4:31 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.

Filing page SEC filing

PENG

Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end

Penguin Solutions, Inc. June 1, 2026, 4:17 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.

Filing page SEC filing

LOGC

ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns

ContextLogic Holdings Inc. June 1, 2026, 4:15 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).

Filing page SEC filing

GRAL

GRAIL appoints Joshua Ofman as CEO with amended compensation and severance

GRAIL, Inc. June 1, 2026, 4:07 PM ET leadership Items 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 8.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended Offer Letter with Dr. Ofman, with the Amended Offer Letter effective as of June 1, 2026 (the “Effective Date”).

Filing page SEC filing

MGNO

Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair

Magnolia Bancorp, Inc. June 1, 2026, 2:15 PM ET leadership Items 5.02, 5.07, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.

Filing page SEC filing

NSC

Norfolk Southern COO John Orr resigns; Brian Barr appointed successor effective June 1

NORFOLK SOUTHERN CORP June 1, 2026, 9:15 AM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 7.01, 9.01 same event type: leadership similar materiality

This filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Comparable filing

On May 31, 2026, John Orr, Executive Vice President & Chief Operating Officer of Norfolk Southern Corporation (the “Company”), notified the Company of his intention to resign from the Company for “good reason” on account of proposed changes in the Company’s operations that would result in a diminution of his duties and responsibilities.

Filing page SEC filing

Source: SEC EDGAR
accession 0001601830-25-000040

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.